financetom
Business
financetom
/
Business
/
Form 8.3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3
Nov 6, 2025 7:16 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

(a) Full name of discloser

BALYASNY ASSET MANAGEMENT L.P.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a)

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates

Use a separate form for each offeror/offeree

Avadel Pharmaceuticals plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)

 

(e) Date position held/dealing undertaken

For an opening position disclosure, state the latest practicable date prior to the disclosure

05/11/2025

(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

 

2. INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security
(Note 3)

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled

1,927,528

1.97

1,443

0.00

(2) Cash-settled derivatives

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/ sell

 

 

 

 

Total

1,927,528

1.97

1,443

0.00

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant
security

Purchase/sale

Number of
securities

Price per unit
(Note 5)

%0.01 ordinary shares

Purchase

337

USD 18.96

%0.01 ordinary shares

Purchase

51

USD 18.96

%0.01 ordinary shares

Purchase

7,575

USD 18.96

%0.01 ordinary shares

Purchase

118,412

USD 18.98

%0.01 ordinary shares

Purchase

7,594

USD 18.96

%0.01 ordinary shares

Purchase

2,868

USD 18.93

%0.01 ordinary shares

Purchase

4,755

USD 18.92

 

(b) Cash-settled derivative transactions

Class of
relevant
security

Product
description
e.g. CFD

Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position

Number of
reference
securities
(Note 6)

Price
per unit
(Note 5)

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of
relevant
security

Product
description e.g. call
option

Writing, purchasing, selling, varying
etc.

Number
of
securities
to which
option
relates
(Note 6)

Exercise
price per
unit

Type
e.g.
American,
European
etc.

Expiry
date

Option
money
paid/
received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of
relevant
security

Product
description
e.g. call
option

Exercising/
exercised
against

Number of
securities

Exercise
price per
unit
(Note 5)

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 3)

Class of
relevant
security

Nature of dealing
e.g. subscription,
conversion, exercise

Details

Price per unit (if
applicable)
(Note 5)

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

(c) Attachments

Is a Supplemental Form 8 attached?

No

Class of relevant security
(Note 3)

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled

1,927,528

1.97

1,443

0.00

(2) Cash-settled derivatives

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/ sell

 

 

 

 

Total

1,927,528

1.97

1,443

0.00

0

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

NOTES ON FORM 8.3

1. See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.

2. See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

3. See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.

4. See the definition of “dealing” in Rule 2.1 of Part A of the Rules.

5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

6. See Rule 2.5(d) of Part A of the Rules.

7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Source: Balyasny Asset Management LP

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Generation Bio Appoints New CFO, Chief Scientific Officer
Generation Bio Appoints New CFO, Chief Scientific Officer
Jan 6, 2025
05:59 PM EST, 01/06/2025 (MT Newswires) -- Generation Bio ( GBIO ) on Monday appointed Kevin Conway as chief financial officer and Phillip Samayoa as chief scientific officer. The company announced the departure of current CFO Matthew Norkunas, effective Friday, and Chief Scientific Officer Matthew Stanton. Prior to his appointment, Conway was vice president for finance at Generation Bio (...
Acurx Launches $2.5 Million Registered Direct Offering; Shares Fall After-Hours
Acurx Launches $2.5 Million Registered Direct Offering; Shares Fall After-Hours
Jan 6, 2025
06:00 PM EST, 01/06/2025 (MT Newswires) -- Acurx Pharmaceuticals ( ACXP ) said late Monday it struck a deal to sell almost 2.5 million shares at $1.015 per share in a registered direct offering to raise some $2.5 million for the late-stage biopharmaceutical company. Acurx also said it will issue warrants in a concurrent private placement to buy up to...
Td Synnex Insider Sold Shares Worth $2,352,327, According to a Recent SEC Filing
Td Synnex Insider Sold Shares Worth $2,352,327, According to a Recent SEC Filing
Jan 6, 2025
06:00 PM EST, 01/06/2025 (MT Newswires) -- Richard T Hume, Director, on January 03, 2025, sold 20,000 shares in Td Synnex ( SNX ) for $2,352,327. Following the Form 4 filing with the SEC, Hume has control over a total of 111,080 shares of the company, with 111,080 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1177394/000112760225000858/xslF345X05/form4.xml ...
Meta elects UFC CEO Dana White, two others to board
Meta elects UFC CEO Dana White, two others to board
Jan 6, 2025
Jan 6 (Reuters) - Meta Platforms ( META ) said on Monday it had elected three new directors to its board, including Dana White, CEO of Ultimate Fighting Championship (UFC) and close friend of President-elect Donald Trump. The Facebook-parent also elected Charlie Songhurst, an investor and former Microsoft executive, as well as John Elkann, CEO of Exor, a holding company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved